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Introduction
Headache is one of the most common disorders occurring in
developmental ages. The prevalence of primary headaches
ranges from 10% to 20% in school-children, and increases
with age: 27%–32% of adolescents (13–14 years of age)
experience headache once a month, and 87%–94% suffer
headache at least once per year.  No sex difference is appar-
ent until age 11 years. Female preponderance begins at
about age 12 years, and during and after adolescence the
female-male ratio is about 2 to 1 [1]. The prevalence of
migraine also increases with age, and estimates range  from
1.2% to 3.2% at age 7 years and 4%–19% at age 15 years
[2–5]. Age-related characteristics need to be taken into
account in analyzing etiology, diagnosis and treatment of
juvenile headache. 
Many topics remain to be detected in childhood and ado-
lescence headache [1], and these aspects should be consid-
ered in the implementation of trials on drug treatment,
because it may help to avoid unexpected results.
The employment of International Headache Society
(IHS) [6] criteria has shown limitations of applicability in
childhood headache. Modifications to the diagnostic para-
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Abstract The introduction of trip-
tans, in the early 1990s, has
improved the therapy for acute
migraine attack, offering a new qual-
ity of life for those patients who suf-
fer from this disabling neurological
disorder. Epidemiological data point
out that about 10% of school-age
children suffer from migraine, with a
progressive increase in incidence
and prevalence up to the threshold of
adulthood. The increase in extent
and prevalence of migraine from the
years of growth stresses the impor-
tance of the application and adjust-
ment of ad hoc therapeutic (either
pharmacological or not) and diag-
nostic measures. Indeed, the peculiar
neurobiological and psychological
aspects which are typical of an
“evolving” organism preclude the
use, by simple “transposition” or
“proportion”, of the knowledge
acquired from adult-targeted studies.
That requires the implementation of
studies to analyze the specific
responses of children and adoles-
cents to the triptans. To date, the
studies on such issues are absolutely
insufficient to draw definitive con-
clusions and indications for the use
of triptans for child and adolescent
migraineurs.
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meters have been discussed both for migraine and tension-
type headache [7–15]. The suggested changes to IHS crite-
ria for the diagnosis of migraine in children refer to shorter
duration, not always unilateral localization, and the variable
occurrence of photophobia and phonophobia. Interestingly,
over time (even at a brief follow-up period) there is a
decreased symptoms overlap and a better fulfilment of IHS
diagnostic parameters, stressing the role of increasing age to
the better fulfilment of the criteria [15]. 
A recent follow-up study [15] of patients initially classi-
fied as IHS 1.7 (patients who meet all criteria for migraine
but one) and 2.3 (patients who meet all criteria for tension-
type but one) showed that, after a brief follow-up period (1.5
years), nearly 30% became headache-free, about 20%
changed IHS category, and the remaining 50% became
migraine or tension-type headache sufferers, as shown by
previous outcome studies [16, 17]. 
The tendency of migraine to spontaneous remission and
the clinical phenomenology of the crises during develop-
mental ages should be considered in the analysis and imple-
mentation of controlled trials. 
A rational drug therapy in children and adolescents
requires individualized treatments, recognizing individual
(age, comorbid disorders, concurrent medications), develop-
mental (pharmacodynamic, pharmacokinetic, pharmacoge-
netic) and environmental (diet, obstacles to compliance) fac-
tors that can influence disposition and response to treatment.
Stage of development markedly influences the absorption,
distribution, metabolism and excretion of drugs [18]. Agents
that work well in adults may provoke different reactions in
children. Safety and tolerability issues need specific atten-
tion, not simple transposition from adult to child or adoles-
cent field. The “whole” always differs from the single sum
of each part.
Several aspects differentiating children and adolescents
from adults should be taken into account in planning a ratio-
nal drug treatment. Taking into consideration these differen-
tial factors is even the sine qua non of the implementation of
controlled trials on drug responses in children and adoles-
cents.
Triptans in children and adolescents: state of the art
The advent of triptans is considered a revolution in the cur-
rent approach to acute migraine treatment [19]. The impor-
tance of studies on triptans concerns both the efficacy of the
drugs and the advancement of our understanding of the
pathophysiology of migraine. 
Triptans are 5-HT1B/1D agonists. Currently, sumatriptan
and zolmitriptan are available, while naratriptan and riza-
triptan are not yet available in all countries. The first triptan
to be developed and most extensively used in adults is suma-
triptan (GR43175, Imitrex). Triptans have proven effective
in adults [20–27], but there are few clear data regarding the
use of triptans in pediatric age.
For prepubertal age, data are scanty and relate particu-
larly to sumatriptan, a triptan with a longer seniority of
use. In the first balanced double-blind design, Hamalainen
et al. [28] failed to prove any significant difference
between drug and placebo. Probably children with
migraine respond differently from adults to the oral admin-
istration of sumatriptan. 
A recent trial [29] highlighted a promising response to
sumatriptan nasal spray (sumatriptan NS 20 mg). Two hours
after medication, a significant pain-free response and relief
from associated symptoms was reported. A second study
employed a prospective open design on a group of 58 chil-
dren (mean age, 8.1 years) [30]. Of 376 attacks treated,
sumatriptan NS reduced migraine pain in 80% of the cases,
nausea in 78%, vomiting in 82%, and phonophobia and pho-
tophobia in 63%; there was an overall clinical improvement
in 79% of cases. The tolerability overlapped with that
observed in adults.
Data relating to the use of triptans in adolescents are, in
part, still unclear. The profile studies (balanced double-blind
design on 701 patients aged 12–17 years) supplied by the
pharmaceutical company with regard to sumatriptan seem
quite conservative [31, 32]. No significant efficacy of suma-
triptan versus placebo has been observed. Furthermore, the
sample showed a significantly lower tolerance than the
group of adult patients.
In two recent studies of sumatriptan NS, one a multi-
centric open-label study [33] and the other a double-blind
study versus placebo [34], sumatriptan was superior to
placebo with regard to headache response and to the recov-
ery of functional disability 2 hours after medication. The
tolerability profiles thereby observed overlapped with those
for adults. A recent open-label study [35] on zolmitriptan
(Zomig) produced data of efficacy and tolerability which
overlapped with those of adults. However, the drug’s half-
life in adolescents was slightly lower than that in adult
patients (3.01 h vs. 3.75 h), probably due to a higher clear-
ance. For this reason, some authors deemed it advisable to
use the lowest dosage (2.5 mg) when treating a pediatric
population [36]. Another open-label study [37] reported a
pain-free headache response 2 hours after medication,
entirely overlapping with that already observed in adult
subjects. 
The occurrence of side effects and the tolerability pro-
file in adolescent patients confirmed the overlap with the
same parameters observed in adults. Typical adverse
events for sumatriptan (subcutaneous) are hot/burning and
pressure sensations, injection site reaction and muscle
stiffness [38]. 
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In general we may state that there is a lack of data from
clinical trials on the use of triptans in the years of growth. It
is also important, as already stated, to have available studies
to clarify the pharmacodynamics and pharmacokinetics of
triptans in patients in the years of growth. Data from the few
available studies highlight that pharmacokinetic mecha-
nisms of triptans in children seem to be different from what
has been observed in the adult population. Sumatriptan is
mainly metabolized by the enzyme MAO-A (monoamine
oxidase A) in the liver [39], but the possible influences of
age on the action of MAO-A are not known [28]. In adults,
sumatriptan causes neuroendocrine changes (increased plas-
ma growth hormone, possible effects on plasma prolactin)
[40, 41], but the neuroendocrine influences in children or
adolescents are not known.
The effect of age on pharmacokinetics of zolmitriptan
metabolites has been recognized in a recent study on young
and elderly adults [42]. The pharmacokinetics of naratriptan
in adolescents showed parameters overlapping to those for
adults [43]. 
Studies on subcutaneous sumatriptan [44, 45] showed
good efficacy in 64%–84% of patients (6–18 years), but
clear data on doses, tolerability and side effects are lacking. 
Summing up, in the studies carried out so far and herein
analyzed, triptans were effective for reducing migraine pain
and symptoms associated with headache pain (e.g. nausea,
vomiting, phonophobia, photophobia) and for decreasing the
times needed to return to normal activities and for the remis-
sion of symptomatology. However, data about the primary
efficacy of triptans (i.e. total remission of pain) are not yet
sufficient. The tolerability and safety rates are comparable to
those observed in adult patients. Side effects are the same in
pediatric and adult populations. In light of the results already
published in the literature, triptans can be used during pedi-
atric age. However, while waiting for further support, priority
use is advised only in those cases in which migraine pain is
“hard” or “impossible” to treat with other analgesic drugs.
The situation is different in adolescence, for which there are
sufficient data suggesting the utility of triptans. It is further-
more advised to give parents and patients precise instructions
on the use of triptans, information on the peculiarity of their
side effects, and the more general specifications of the drug.
Future directions
Drug treatment in pediatric age should always take into
account that age-related differences markedly influence the
absorption, distribution, metabolism and excretion of drugs.
Recognizing individual (age, comorbid disorders, psycho-
logical factors) and developmental (pharmacodynamic,
pharmacokinetic, pharmacogenetic) factors that can influ-
ence disposition and response to the treatment is a pressing
task, requiring  pediatric age goal-directed studies. 
Good results for the use of triptans in children and ado-
lescents have emerged from open-label studies, but evidence
from placebo-controlled, double-blind, randomized, cross-
over trials are absolutely required. Moreover, most data are
available only in abstract form.
Clinical trials on pediatric patients are lacking, and the
findings are unsatisfactory. There have been no clinical tri-
als testing the efficacy of different triptans. Studies compar-
ing the efficacy of triptans to that of other analgesic drugs
with tested efficacy are also needed. 
The effect of age in the proband samples should be con-
sidered with more attention, because samples usually com-
prise subjects of pre-pubertal and post-pubertal age.
The presence of “pure” and easily diagnosed migraine
according to IHS criteria, instead of mixed types or forms
intercalated to (episodic or chronic) tension-type headache,
should be carefully assessed, because it may represent fac-
tors influencing the efficacy of the triptan.
Analyzing the characteristics of non-responders is anoth-
er issue to consider in order to understand factors influenc-
ing drug efficacy and tolerability. The presence of psychi-
atric comorbidity should be assessed, also considering the
negative implications for the prognosis [46]. 
Family and school environments, likely secondary gains
related to migraine crises, may play an important role in
influencing the course of the crises. Issues related to com-
pliance should be carefully analyzed in children and adoles-
cents. Indications for correct triptan intake should be
absolutely given.
Another aspect that merits attention is the high rate of
response to placebo, because it opens per se the importance
of psychological factors in influencing head pain. Moreover,
the response rate to placebo (vs. oral sumatriptan) seems to
be lower in children [47] than in adolescents [28]. Studies
on triptans of established efficacy in adults (most of all riza-
triptan) [48–50] are absolutely lacking for child and adoles-
cent patients.
A better comprehension of the biological mechanisms
related to the responses to placebo (“how does placebo real-
ly work?”) and the likely influence of age on it may help
explain the etiopathogenesis of migraine.
In extreme synthesis, the current state of research on the
use of triptans for child and adolescent migraine does not
lead to definitive conclusions. Many points need further
examination towards the objective of giving “the best drug
to each patient” according to the individual characteristics.
Clearly, that issue assumes particular shadows in children
and adolescents, for whom personal characteristics (e.g. bio-
logical, psychological) are strictly embedded with the clini-
cal age-related phenomenology of headache crises, in a
“crossing-over” of difficult framing and decoding.
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